The University of Chicago Header Logo

Stanley Liauw

Concepts (311)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Prostatic Neoplasms
73
2026
1846
10.330
Why?
Radiotherapy, Intensity-Modulated
24
2026
200
4.980
Why?
Androgen Antagonists
22
2026
157
3.840
Why?
Radiation Injuries
10
2026
160
3.690
Why?
Prostatectomy
27
2026
491
3.520
Why?
Neoplasm Recurrence, Local
23
2026
1538
2.750
Why?
Salvage Therapy
18
2026
241
2.560
Why?
Prostate-Specific Antigen
26
2026
356
2.460
Why?
Anus Neoplasms
5
2022
41
2.440
Why?
Adenocarcinoma
17
2019
1215
2.420
Why?
Radiotherapy Dosage
29
2025
478
2.380
Why?
Chemoradiotherapy
7
2021
337
2.270
Why?
Radiotherapy, Image-Guided
6
2025
66
1.920
Why?
Quality of Life
9
2026
1904
1.890
Why?
Radiosurgery
7
2025
352
1.740
Why?
Rectal Neoplasms
6
2026
139
1.720
Why?
Radiotherapy, Conformal
7
2016
88
1.660
Why?
Aged
69
2026
21986
1.560
Why?
Male
101
2026
47475
1.470
Why?
Fiducial Markers
3
2025
12
1.450
Why?
Aged, 80 and over
37
2025
7461
1.430
Why?
Urinary Incontinence
4
2016
226
1.420
Why?
Radiotherapy, Adjuvant
11
2018
325
1.390
Why?
Anticoagulants
5
2022
486
1.360
Why?
Middle Aged
71
2026
29642
1.350
Why?
Follow-Up Studies
24
2026
4049
1.330
Why?
Urinary Bladder Neoplasms
6
2024
403
1.280
Why?
Antineoplastic Agents, Hormonal
5
2024
161
1.200
Why?
Humans
122
2026
98799
1.200
Why?
Prostate
7
2023
434
1.100
Why?
Patient Reported Outcome Measures
3
2026
337
1.080
Why?
Brachytherapy
9
2025
139
1.070
Why?
Head and Neck Neoplasms
6
2021
1091
1.040
Why?
Neoplasm Staging
23
2023
2087
1.010
Why?
Radiotherapy Planning, Computer-Assisted
4
2025
215
1.000
Why?
Combined Modality Therapy
23
2026
1754
0.990
Why?
Tomography, X-Ray Computed
7
2025
2680
0.950
Why?
Papillomavirus Infections
2
2021
311
0.950
Why?
Carcinoma, Renal Cell
4
2025
384
0.910
Why?
Antineoplastic Combined Chemotherapy Protocols
9
2026
2666
0.910
Why?
Radiotherapy
9
2019
325
0.910
Why?
Fluorouracil
7
2017
543
0.900
Why?
Urogenital System
4
2014
11
0.890
Why?
Gonadotropin-Releasing Hormone
2
2024
100
0.870
Why?
Capecitabine
5
2024
103
0.860
Why?
Kidney Neoplasms
4
2025
556
0.840
Why?
Treatment Outcome
28
2026
9806
0.830
Why?
5-alpha Reductase Inhibitors
1
2024
12
0.820
Why?
Carcinoma, Hepatocellular
2
2022
455
0.810
Why?
Platelet Aggregation Inhibitors
3
2022
194
0.780
Why?
Rectal Diseases
3
2013
25
0.760
Why?
Liver Neoplasms
3
2022
840
0.760
Why?
Antimetabolites, Antineoplastic
2
2018
246
0.740
Why?
Cooperative Behavior
1
2023
199
0.720
Why?
Prospective Studies
10
2026
4837
0.700
Why?
Magnetic Resonance Imaging
4
2026
3622
0.700
Why?
Organs at Risk
4
2025
55
0.700
Why?
Radiation Oncology
4
2021
130
0.690
Why?
Aspirin
2
2013
168
0.680
Why?
Gastrointestinal Tract
3
2013
198
0.670
Why?
Pancreatic Neoplasms
4
2017
782
0.650
Why?
Patient Care Team
1
2023
318
0.640
Why?
Risk Assessment
12
2020
2604
0.640
Why?
Urinary Bladder
3
2024
263
0.640
Why?
Chemoradiotherapy, Adjuvant
3
2017
40
0.630
Why?
Carcinoma, Squamous Cell
5
2018
1107
0.630
Why?
Cystectomy
4
2024
125
0.620
Why?
Hypersensitivity
1
2022
167
0.620
Why?
Long Term Adverse Effects
1
2019
7
0.590
Why?
Oropharyngeal Neoplasms
1
2021
152
0.590
Why?
Analysis of Variance
9
2015
890
0.590
Why?
Rectum
4
2014
152
0.580
Why?
Retrospective Studies
26
2026
11104
0.580
Why?
Lymph Node Excision
4
2017
238
0.570
Why?
Prognosis
16
2024
4139
0.560
Why?
Neoplasm Grading
9
2022
425
0.560
Why?
Hematuria
3
2022
53
0.560
Why?
Cohort Studies
9
2025
3242
0.560
Why?
Image Processing, Computer-Assisted
2
2025
1305
0.550
Why?
Adult
33
2025
29698
0.550
Why?
Neoadjuvant Therapy
4
2026
477
0.540
Why?
Urologic Neoplasms
1
2018
82
0.520
Why?
Time Factors
15
2020
5586
0.500
Why?
Leukopenia
1
2016
66
0.490
Why?
Organ Transplantation
1
2020
307
0.480
Why?
Pelvic Bones
1
2016
46
0.470
Why?
Chemotherapy, Adjuvant
6
2015
527
0.460
Why?
Thrombocytopenia
1
2016
194
0.450
Why?
Risk Factors
10
2020
6295
0.440
Why?
Immunosuppressive Agents
1
2020
1021
0.440
Why?
Bone Marrow
1
2016
419
0.430
Why?
Sexuality
1
2014
40
0.420
Why?
Multivariate Analysis
8
2017
1007
0.410
Why?
Biomarkers, Tumor
3
2012
1786
0.410
Why?
Tumor Burden
5
2019
330
0.410
Why?
Lymphatic Metastasis
6
2024
519
0.390
Why?
Gastrointestinal Hemorrhage
2
2013
251
0.390
Why?
Survival Rate
9
2019
2057
0.390
Why?
Antineoplastic Agents
7
2019
2386
0.380
Why?
Urinary Retention
2
2010
43
0.380
Why?
Herpes Zoster
1
2013
26
0.380
Why?
Transurethral Resection of Prostate
2
2010
11
0.380
Why?
CA-19-9 Antigen
1
2012
14
0.370
Why?
Hospitalization
1
2018
993
0.360
Why?
SEER Program
6
2020
252
0.360
Why?
Chemoprevention
1
2012
93
0.360
Why?
Carcinoembryonic Antigen
1
2012
40
0.360
Why?
Portal Vein
1
2012
122
0.350
Why?
Kaplan-Meier Estimate
8
2017
909
0.350
Why?
Diabetes Complications
1
2013
176
0.350
Why?
Risk
4
2020
662
0.340
Why?
Radioimmunodetection
2
2008
12
0.330
Why?
Deoxycytidine
2
2012
218
0.330
Why?
Postoperative Complications
2
2020
2719
0.330
Why?
Neoplasm Metastasis
4
2025
1102
0.330
Why?
Prostatism
1
2010
5
0.320
Why?
Female
26
2026
51997
0.320
Why?
Lymph Nodes
3
2020
563
0.320
Why?
Urination Disorders
1
2010
52
0.310
Why?
Gastrointestinal Neoplasms
3
2021
114
0.310
Why?
Body Burden
1
2009
10
0.300
Why?
Venous Thrombosis
1
2012
265
0.300
Why?
Withholding Treatment
1
2010
130
0.300
Why?
Practice Guidelines as Topic
1
2016
1116
0.300
Why?
Survival Analysis
9
2019
1530
0.290
Why?
Dose-Response Relationship, Radiation
4
2016
193
0.290
Why?
Smoking
1
2013
676
0.280
Why?
Leucovorin
3
2017
205
0.280
Why?
Models, Statistical
1
2012
602
0.280
Why?
Comorbidity
3
2021
1037
0.270
Why?
Pelvis
2
2026
106
0.260
Why?
Hemorrhage
1
2009
297
0.250
Why?
Ganglioglioma
1
2006
9
0.250
Why?
Disease Progression
3
2020
1621
0.250
Why?
Neoplasm, Residual
4
2026
205
0.240
Why?
Disease-Free Survival
7
2014
1196
0.240
Why?
Treatment Failure
4
2016
300
0.240
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2010
406
0.240
Why?
Carcinoma
2
2012
442
0.230
Why?
Testicular Neoplasms
2
2019
126
0.230
Why?
Neoplasms, Radiation-Induced
1
2006
96
0.230
Why?
Abdomen
1
2006
121
0.230
Why?
Positron Emission Tomography Computed Tomography
3
2025
108
0.230
Why?
Postoperative Period
3
2015
325
0.230
Why?
Disease Management
3
2024
378
0.220
Why?
Proportional Hazards Models
5
2017
925
0.210
Why?
Lymphoma, Non-Hodgkin
1
2006
262
0.210
Why?
Leuprolide
1
2024
34
0.210
Why?
United States
7
2021
8387
0.210
Why?
Probability
3
2012
356
0.210
Why?
Neoplasms, Second Primary
1
2006
244
0.210
Why?
Urethral Neoplasms
2
2018
10
0.200
Why?
Motion
1
2023
96
0.190
Why?
Patient Selection
3
2017
725
0.190
Why?
Phenylthiohydantoin
2
2022
58
0.190
Why?
Contrast Media
2
2016
1014
0.180
Why?
Ipilimumab
1
2022
69
0.180
Why?
Pilot Projects
1
2025
978
0.180
Why?
Propensity Score
2
2020
218
0.180
Why?
Severity of Illness Index
4
2013
2025
0.170
Why?
Radiation Oncologists
2
2021
15
0.170
Why?
Incidence
2
2022
1798
0.170
Why?
Ticlopidine
2
2012
25
0.170
Why?
Radium
1
2020
7
0.160
Why?
Oncologists
1
2021
43
0.160
Why?
Brain Neoplasms
1
2006
845
0.160
Why?
Warfarin
2
2012
109
0.160
Why?
Platelet Count
1
2020
94
0.150
Why?
Neoplasm Invasiveness
4
2024
583
0.150
Why?
Internship and Residency
2
2021
1132
0.150
Why?
Radiologic Health
1
2019
2
0.150
Why?
Androgen Receptor Antagonists
1
2019
21
0.150
Why?
Sezary Syndrome
1
2019
12
0.150
Why?
Depsipeptides
1
2019
30
0.140
Why?
Mycosis Fungoides
1
2019
30
0.140
Why?
Electrons
1
2019
52
0.140
Why?
Mitomycin
2
2016
30
0.140
Why?
Feasibility Studies
1
2021
818
0.140
Why?
Thoracic Vertebrae
1
2019
89
0.140
Why?
Transplantation Conditioning
1
2020
389
0.140
Why?
Proctoscopy
1
2017
1
0.130
Why?
Prostatic Diseases
1
2017
2
0.130
Why?
Digital Rectal Examination
1
2017
5
0.130
Why?
Spinal Neoplasms
1
2019
128
0.130
Why?
Movement
1
2020
317
0.130
Why?
Colorectal Neoplasms
1
2006
1120
0.130
Why?
Prostatic Neoplasms, Castration-Resistant
1
2019
121
0.130
Why?
Organoplatinum Compounds
1
2017
95
0.130
Why?
Clinical Competence
3
2021
873
0.130
Why?
Surveys and Questionnaires
4
2021
3058
0.130
Why?
Phantoms, Imaging
1
2020
493
0.130
Why?
Sensitivity and Specificity
3
2016
1946
0.120
Why?
Neoplasms
1
2013
3382
0.120
Why?
Carcinoma, Transitional Cell
1
2018
158
0.120
Why?
Postoperative Care
1
2018
239
0.120
Why?
Nephrectomy
1
2019
291
0.120
Why?
Camptothecin
1
2017
198
0.120
Why?
Internationality
1
2016
80
0.120
Why?
Remission Induction
1
2018
764
0.120
Why?
Organ Sparing Treatments
1
2016
54
0.120
Why?
Ilium
1
2016
32
0.120
Why?
Reproducibility of Results
3
2017
2799
0.120
Why?
Medicare
1
2020
528
0.120
Why?
Immunotherapy
1
2022
831
0.120
Why?
Neutropenia
1
2016
211
0.120
Why?
Patient Safety
1
2018
237
0.120
Why?
Urology
1
2017
145
0.110
Why?
Software
1
2020
698
0.110
Why?
Seminoma
1
2015
15
0.110
Why?
Orchiectomy
1
2015
63
0.110
Why?
Drug Administration Schedule
1
2016
837
0.110
Why?
Transcriptome
1
2021
828
0.110
Why?
Phosphodiesterase Inhibitors
1
2014
30
0.110
Why?
Neoplasms, Germ Cell and Embryonal
1
2015
64
0.100
Why?
Quality Improvement
1
2019
538
0.100
Why?
Carboplatin
1
2015
331
0.100
Why?
Kidney
1
2019
1126
0.100
Why?
Health Surveys
1
2014
254
0.100
Why?
Skin Neoplasms
1
2019
638
0.100
Why?
Education, Medical, Graduate
1
2017
455
0.100
Why?
Radiography
2
2006
763
0.090
Why?
Cyclooxygenase 2 Inhibitors
1
2013
36
0.090
Why?
Metalloporphyrins
1
2012
26
0.090
Why?
Enoxaparin
1
2012
27
0.090
Why?
Prevalence
1
2016
1396
0.090
Why?
Constriction, Pathologic
1
2013
214
0.090
Why?
Diagnostic Imaging
1
2016
468
0.090
Why?
Lower Urinary Tract Symptoms
1
2013
90
0.090
Why?
Regression Analysis
2
2017
578
0.080
Why?
Age Factors
3
2010
1976
0.080
Why?
Genetic Vectors
1
2012
425
0.080
Why?
Curriculum
1
2016
643
0.080
Why?
Proctitis
1
2010
12
0.080
Why?
Students, Medical
1
2016
450
0.080
Why?
Neck Dissection
2
2008
67
0.080
Why?
Algorithms
2
2019
2005
0.080
Why?
Stomach Neoplasms
1
2014
321
0.080
Why?
Nitriles
2
2022
172
0.080
Why?
Longitudinal Studies
1
2014
1305
0.080
Why?
Radiotherapy, High-Energy
1
2010
43
0.080
Why?
Seminal Vesicles
2
2016
40
0.080
Why?
Antiviral Agents
1
2013
369
0.080
Why?
Genetic Therapy
1
2012
374
0.080
Why?
Benzamides
2
2022
260
0.080
Why?
Predictive Value of Tests
2
2006
1792
0.080
Why?
Breast Neoplasms
1
2004
3303
0.070
Why?
Tumor Necrosis Factor-alpha
1
2012
712
0.070
Why?
Urologic Diseases
1
2009
38
0.070
Why?
Thymidine Phosphorylase
1
2008
4
0.070
Why?
Vitamin B Complex
1
2008
22
0.070
Why?
Registries
3
2010
1133
0.070
Why?
Acute Disease
1
2010
864
0.070
Why?
Indium Radioisotopes
1
2007
9
0.060
Why?
Young Adult
3
2019
7598
0.060
Why?
Pharynx
1
2006
44
0.060
Why?
Thiohydantoins
1
2026
4
0.060
Why?
Abiraterone Acetate
1
2026
14
0.060
Why?
Iodine Radioisotopes
1
2006
145
0.060
Why?
Cisplatin
2
2024
578
0.060
Why?
Recurrence
1
2009
1274
0.060
Why?
Prednisone
1
2026
252
0.060
Why?
Re-Irradiation
1
2025
18
0.060
Why?
Infusions, Intravenous
1
2005
403
0.050
Why?
Chicago
1
2009
1520
0.050
Why?
Sampling Studies
1
2004
75
0.050
Why?
Palliative Care
1
2006
291
0.050
Why?
Digestive System
1
2003
42
0.050
Why?
Guanidines
1
2022
34
0.050
Why?
Physics
1
2021
21
0.040
Why?
Mastectomy
1
2004
277
0.040
Why?
Androgens
1
2021
164
0.040
Why?
Patient Care Planning
1
2021
92
0.040
Why?
Piperazines
1
2022
308
0.040
Why?
Perception
1
2021
190
0.040
Why?
Cell Cycle
1
2021
519
0.040
Why?
Diffusion Magnetic Resonance Imaging
1
2021
305
0.040
Why?
Retreatment
1
2019
106
0.040
Why?
Placebos
1
2019
210
0.040
Why?
Child, Preschool
1
2006
4053
0.040
Why?
Multicenter Studies as Topic
1
2019
195
0.040
Why?
Clinical Trials, Phase II as Topic
1
2019
168
0.030
Why?
Aftercare
1
2019
93
0.030
Why?
Kallikreins
1
2017
47
0.030
Why?
Efficiency
1
2017
39
0.030
Why?
Inflammation
1
2004
1134
0.030
Why?
Delphi Technique
1
2017
183
0.030
Why?
Radiometry
1
2016
64
0.030
Why?
Equipment Design
1
2017
428
0.030
Why?
Job Satisfaction
1
2017
87
0.030
Why?
Ultrasonography, Interventional
1
2016
125
0.030
Why?
Sample Size
1
2016
130
0.030
Why?
Texas
1
2016
137
0.030
Why?
Chi-Square Distribution
1
2016
361
0.030
Why?
Insurance, Health
1
2017
192
0.030
Why?
Odds Ratio
1
2017
728
0.030
Why?
Double-Blind Method
1
2019
1793
0.030
Why?
Randomized Controlled Trials as Topic
1
2019
995
0.030
Why?
Child
1
2006
7771
0.030
Why?
Radiopharmaceuticals
1
2016
214
0.030
Why?
Internet
1
2017
359
0.030
Why?
Educational Measurement
1
2016
243
0.030
Why?
Preoperative Period
1
2014
103
0.030
Why?
Adolescent
1
2006
10168
0.020
Why?
Fatigue
1
2013
187
0.020
Why?
Databases, Factual
1
2016
1102
0.020
Why?
Cell Differentiation
2
2008
1656
0.020
Why?
Health Services Accessibility
1
2014
548
0.020
Why?
Nomograms
1
2007
34
0.020
Why?
Radiation Dosage
1
2007
233
0.010
Why?
Case-Control Studies
1
2008
2017
0.010
Why?
Clinical Trials as Topic
1
2008
1128
0.010
Why?
Liauw's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (311)
Explore
_
Co-Authors (52)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_